Evidence map›Paper›PMID 36327757›Full record

ArticleESMO open2022

Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials.

E Dell'Aquila, D Rossini, C A M Fulgenzi, A Passardi, E Tamburini, G Vetere, M Carullo, F Citarella, C Antoniotti, A Zaniboni and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 11 institutions in 1 country.

E Dell'AquilaMedical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy; Department of Medical Oncology, University Campus Bio-Medico of Rome, Rome, Italy.
D RossiniUnit of Oncology, University Hospital of Pisa, Pisa, Italy; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
C A M FulgenziDepartment of Medical Oncology, University Campus Bio-Medico of Rome, Rome, Italy.
A PassardiDepartment of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori', Meldola, Italy.
E TamburiniDepartment of Oncology and Palliative Care, Cardinale G. Panico Tricase City Hospital, Tricase, Italy.
G VetereUnit of Oncology, University Hospital of Pisa, Pisa, Italy; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
M CarulloUnit of Oncology, University Hospital of Pisa, Pisa, Italy; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
F CitarellaDepartment of Medical Oncology, University Campus Bio-Medico of Rome, Rome, Italy.
C AntoniottiUnit of Oncology, University Hospital of Pisa, Pisa, Italy; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
A ZaniboniMedical Oncology Unit, Fondazione Poliambulanza, Brescia, Italy.
F PietrantonioDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
A SpagnolettiDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
F MarmorinoUnit of Oncology, University Hospital of Pisa, Pisa, Italy; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
B BorelliUnit of Oncology, University Hospital of Pisa, Pisa, Italy; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
G AllegriniDepartment of Oncology, Division of Medical Oncology, Azienda USL Toscana Nord Ovest, Livorno, Italy.
S LonardiOncology Unit 3, Department of Oncology, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.
F NappoOncology Unit 1, Department of Oncology, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.
G MasiUnit of Oncology, University Hospital of Pisa, Pisa, Italy; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
C CremoliniUnit of Oncology, University Hospital of Pisa, Pisa, Italy; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy. Electronic address: chiara.cremolini@gmail.com.
D SantiniDepartment of Medical Oncology, University Campus Bio-Medico of Rome, Rome, Italy; Department of Radiology, Oncology and Pathology, Policlinico Umberto, I Sapienza University of Rome, Rome, Italy.
Azienda Ospedaliera Universitaria Pisana · ITUniversity of Pisa · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITIstituto Oncologico Veneto · ITUniversità Campus Bio-Medico · ITAzienda Usl Toscana Centro · ITFondazione Poliambulanza Istituto Ospedaliero · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITOspedale di Cattinara · ITSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) is one of the most common cancers; ∼20% of patients have metastases at diagnosis, and 50%-60% subsequently develop metachronous metastases. Bone involvement, despite being rare, is usually associated with higher disease burden, worse prognosis, impaired quality of life, and significant health-related cost. In the last few years, following the positive results of the TRIBE and TRIBE2 trials, the association of FOLFOXIRI plus bevacizumab has become the new standard of care for metastatic CRC. Despite being highly efficacious in all subgroups, little is known about the activity of this regimen in patients with bone metastases. PATIENTS AND

methodsWe carried out a pooled analysis of TRIBE and TRIBE2 studies focusing on patients with skeletal deposits.

resultsOur analyses on the whole population showed that patients with baseline bone involvement reported shorter overall survival [OS; 14.0 versus 26.2 months; hazard ratio (HR) 2.04, 95% confidence interval (CI) 1.46-2.87; P < 0.001] and progression-free survival (PFS; 6.2 versus 11.1 months; HR 1.96, 95% CI 1.42-2.69; P < 0.001) compared with those without bone metastases; no significant interaction with the treatment was reported for PFS (P = 0.094) and OS (P = 0.38). Bone metastases had a negative prognostic implication in the multivariate analysis (HR 2.24, 95% CI 1.54-3.26; P < 0.001). Furthermore, patients with bone lesions at first radiological progression (including those with baseline bone metastases) had a shorter OS compared with those who progressed in other sites (10.4 versus 13.2 months; HR 1.48, 95% CI 1.15-1.91; P = 0.002). A trend toward inferior OS (7.5 versus 11 months, HR 1.50, 95% CI 0.92-2.45; P = 0.10) appeared in patients with basal skeletal deposits compared with those with bone involvement at first radiological progression.

conclusionsOur study confirmed the negative prognostic impact of bone metastases in CRC. Furthermore, we demonstrated for the first time that the survival advantage of triplet chemotherapy plus bevacizumab is maintained even in this prognostically unfavorable subgroup.

Indexed as

Bone NeoplasmsColonic NeoplasmsColorectal NeoplasmsBevacizumabCamptothecinFluorouracilHumansPrognosisQuality of LifeBevacizumabCamptothecinFluorouracilbone metastasescolorectal cancerprognosistriplet chemotherapy

Identifiers

PMID36327757
PMCPMC9808439
OpenAlexW4307697957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.